Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 437

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Open access
Lee, Matthew M.Y., Brooksbank, Katriona J.M., Wetherall, Kirsty, Mangion, Kenneth, Roditi, Giles, Campbell, Ross T., Berry, Colin, Chong, Victor, Coyle, Liz, Docherty, Kieran F., Dreisbach, John G., Labinjoh, Catherine, Lang, Ninian N., Lennie, Vera, McConnachie, Alex, Murphy, Clare L., Petrie, Colin J., Petrie, John R., Speirits, Iain A., Sourbron, Steven, Welsh, Paul, Woodward, Rosemary, Radjenovic, Aleksandra, Mark, Patrick B., McMurray, John J.V., Jhund, Pardeep S., Petrie, Mark C., Sattar, Naveed·2021·Circulation

Abstract

Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain. Methods: We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes. Patients were randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and ≥65 years) and glycemic status (diabetes or prediabetes). The coprimary outcomes were change from baseline to 36 weeks in LV end-systolic volume indexed to body surface area and LV global longitudinal strain both measured using cardiovascular magnetic resonance. Secondary efficacy outcomes included other cardiovascular magnetic resonance measures (LV end-diastolic volume index, LV ejection fraction), diuretic intensification, symptoms (Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, B-lines on lung ultrasound, and biomarkers (including N-terminal pro-B-type natriuretic peptide). Results: From April 2018 to August 2019, 105 patients were randomly assigned: mean age 68.7 (SD, 11.1) years, 77 (73.3%) male, 82 (78.1%) diabetes and 23 (21.9%) prediabetes, mean LV ejection fraction 32.5% (9.8%), and 81 (77.1%) New York Heart Association II and 24 (22.9%) New York Heart Association III. Patients received standard treatment for HFrEF. In comparison with placebo, empagliflozin reduced LV end-systolic volume index by 6.0 (95% CI, –10.8 to –1.2) mL/m 2 ( P =0.015). There was no difference in LV global longitudinal strain. Empagliflozin reduced LV end-diastolic volume index by 8.2 (95% CI, –13.7 to –2.6) mL/m 2 ( P =0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%–47%), P =0.038. There were no between-group differences in other cardiovascular magnetic resonance measures, diuretic intensification, Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, or B-lines. Conclusions: The sodium-glucose cotransporter 2 inhibitor empagliflozin reduced LV volumes in patients with HFrEF and type 2 diabetes or prediabetes. Favorable reverse LV remodeling may be a mechanism by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03485092.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.120.052186

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 437

Metadata

Authors
Lee, M. M. Y., Brooksbank, K. J. M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R. T., Berry, C., Chong, V., Coyle, L., Docherty, K. F., Dreisbach, J. G., Labinjoh, C., Lang, N. N., Lennie, V., McConnachie, A., Murphy, C. L., Petrie, C. J., Petrie, J. R., Speirits, I. A., Sourbron, S., Welsh, P., Woodward, R., Radjenovic, A., Mark, P. B., McMurray, J. J. V., Jhund, P. S., Petrie, M. C., & Sattar, N.
Venue
Circulation
Published
2021-02-09
Volume
143
Issue
6
Pages
516-525
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3098234982
Cited by
437
References
28
FWCI
34.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). https://app.cochat.ai/papers/10.1161/circulationaha.120.052186
The paper
Lee, M. M. Y., Brooksbank, K. J. M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R. T., Berry, C., Chong, V., Coyle, L., Docherty, K. F., Dreisbach, J. G., Labinjoh, C., Lang, N. N., Lennie, V., McConnachie, A., Murphy, C. L., Petrie, C. J., Petrie, J. R., Speirits, I. A., . . . Sattar, N. (2021). Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. https://doi.org/10.1161/circulationaha.120.052186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.